Literature DB >> 20154697

An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

Junxia Min1, Alexander Zaslavsky, Giuseppe Fedele, Sara K McLaughlin, Elizabeth E Reczek, Thomas De Raedt, Isil Guney, David E Strochlic, Laura E Macconaill, Rameen Beroukhim, Roderick T Bronson, Sandra Ryeom, William C Hahn, Massimo Loda, Karen Cichowski.   

Abstract

Metastasis is responsible for the majority of prostate cancer-related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene-tumor suppressor cascade that promotes prostate cancer growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-kappaB (NF-kappaB). Specifically, we show that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-kappaB through distinct domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-kappaB and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20154697      PMCID: PMC2903662          DOI: 10.1038/nm.2100

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  48 in total

1.  Ral GTPases contribute to regulation of cyclin D1 through activation of NF-kappaB.

Authors:  D O Henry; S A Moskalenko; K J Kaur; M Fu; R G Pestell; J H Camonis; M A White
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

Review 2.  The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?

Authors:  William R Sellers; Massimo Loda
Journal:  Cancer Cell       Date:  2002-11       Impact factor: 31.743

Review 3.  Epithelial-mesenchymal transitions in tumour progression.

Authors:  Jean Paul Thiery
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

4.  Gene expression analysis of prostate cancers.

Authors:  Jian-Hua Luo; Yan Ping Yu; Kathleen Cieply; Fan Lin; Petrina Deflavia; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich
Journal:  Mol Carcinog       Date:  2002-01       Impact factor: 4.784

5.  The polycomb group protein EZH2 is involved in progression of prostate cancer.

Authors:  Sooryanarayana Varambally; Saravana M Dhanasekaran; Ming Zhou; Terrence R Barrette; Chandan Kumar-Sinha; Martin G Sanda; Debashis Ghosh; Kenneth J Pienta; Richard G A B Sewalt; Arie P Otte; Mark A Rubin; Arul M Chinnaiyan
Journal:  Nature       Date:  2002-10-10       Impact factor: 49.962

Review 6.  Mouse models of prostate carcinogenesis.

Authors:  Cory Abate-Shen; Michael M Shen
Journal:  Trends Genet       Date:  2002-05       Impact factor: 11.639

7.  Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.

Authors:  Shazli N Malik; Michael Brattain; Paramita M Ghosh; Dean A Troyer; Thomas Prihoda; Roble Bedolla; Jeffrey I Kreisberg
Journal:  Clin Cancer Res       Date:  2002-04       Impact factor: 12.531

8.  Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines.

Authors:  Hong Chen; Shinichi Toyooka; Adi F Gazdar; Jer-Tsong Hsieh
Journal:  J Biol Chem       Date:  2002-11-21       Impact factor: 5.157

9.  Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression.

Authors:  Donkena Krishna Vanaja; John C Cheville; Steve J Iturria; Charles Y F Young
Journal:  Cancer Res       Date:  2003-07-15       Impact factor: 12.701

10.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.

Authors:  David A Barbie; Pablo Tamayo; Jesse S Boehm; So Young Kim; Susan E Moody; Ian F Dunn; Anna C Schinzel; Peter Sandy; Etienne Meylan; Claudia Scholl; Stefan Fröhling; Edmond M Chan; Martin L Sos; Kathrin Michel; Craig Mermel; Serena J Silver; Barbara A Weir; Jan H Reiling; Qing Sheng; Piyush B Gupta; Raymond C Wadlow; Hanh Le; Sebastian Hoersch; Ben S Wittner; Sridhar Ramaswamy; David M Livingston; David M Sabatini; Matthew Meyerson; Roman K Thomas; Eric S Lander; Jill P Mesirov; David E Root; D Gary Gilliland; Tyler Jacks; William C Hahn
Journal:  Nature       Date:  2009-10-21       Impact factor: 49.962

View more
  192 in total

1.  Histone methyltransferase NSD2/MMSET mediates constitutive NF-κB signaling for cancer cell proliferation, survival, and tumor growth via a feed-forward loop.

Authors:  Ping Yang; Linlang Guo; Zhijian J Duan; Clifford G Tepper; Ling Xue; Xinbin Chen; Hsing-Jien Kung; Allen C Gao; June X Zou; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

Review 2.  Histone methyltransferase and histone methylation in inflammatory T-cell responses.

Authors:  Shan He; Qing Tong; Dennis Keith Bishop; Yi Zhang
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

3.  Inhibition of EZH2 expression is associated with the proliferation, apoptosis and migration of SW620 colorectal cancer cells in vitro.

Authors:  He Song-Bing; Zhou Hao; Zhou Jian; Zhou Guo-Qiang; Han Tuo; Wan Dai-Wei; Gu Wen; Gao Lin; Zhang Yi; Xue Xiao-Feng; Zhang Li-Feng; Fei Min; Hi Shui-Qing; Yang Xiao-Dong; Zhu Xin-Guo; Wang Liang; Li De-Chun
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-27

4.  The RasGAP gene, RASAL2, is a tumor and metastasis suppressor.

Authors:  Sara Koenig McLaughlin; Sarah Naomi Olsen; Benjamin Dake; Thomas De Raedt; Elgene Lim; Roderick Terry Bronson; Rameen Beroukhim; Kornelia Polyak; Myles Brown; Charlotte Kuperwasser; Karen Cichowski
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

Review 5.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

6.  A transcriptional repressor co-regulatory network governing androgen response in prostate cancers.

Authors:  Kern Rei Chng; Cheng Wei Chang; Si Kee Tan; Chong Yang; Shu Zhen Hong; Noel Yan Wei Sng; Edwin Cheung
Journal:  EMBO J       Date:  2012-04-24       Impact factor: 11.598

7.  Short AIP1 (ASK1-Interacting Protein-1) Isoform Localizes to the Mitochondria and Promotes Vascular Dysfunction.

Authors:  Zheng Li; Li Li; Haifeng Zhang; Huanjiao Jenny Zhou; Weidong Ji; Wang Min
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-10-17       Impact factor: 8.311

Review 8.  Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.

Authors:  Kathryn E Ware; Mariano A Garcia-Blanco; Andrew J Armstrong; Scott M Dehm
Journal:  Endocr Relat Cancer       Date:  2014-05-23       Impact factor: 5.678

9.  Histone demethylase RBP2 is critical for breast cancer progression and metastasis.

Authors:  Jian Cao; Zongzhi Liu; William K C Cheung; Minghui Zhao; Sophia Y Chen; Siew Wee Chan; Carmen J Booth; Don X Nguyen; Qin Yan
Journal:  Cell Rep       Date:  2014-02-27       Impact factor: 9.423

Review 10.  AIP1 in graft arteriosclerosis.

Authors:  Wang Min; Jordan S Pober
Journal:  Trends Cardiovasc Med       Date:  2011-11       Impact factor: 6.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.